BRPI0912043A2 - métodos de tratamento de doença associada à cinesina meiótica - Google Patents
métodos de tratamento de doença associada à cinesina meióticaInfo
- Publication number
- BRPI0912043A2 BRPI0912043A2 BRPI0912043A BRPI0912043A BRPI0912043A2 BR PI0912043 A2 BRPI0912043 A2 BR PI0912043A2 BR PI0912043 A BRPI0912043 A BR PI0912043A BR PI0912043 A BRPI0912043 A BR PI0912043A BR PI0912043 A2 BRPI0912043 A2 BR PI0912043A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- methods
- associated disease
- meiotic kinesin
- meiotic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5759008P | 2008-05-30 | 2008-05-30 | |
PCT/US2009/045406 WO2009155025A1 (en) | 2008-05-30 | 2009-05-28 | Methods of treating a meiotic kinesin-associated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0912043A2 true BRPI0912043A2 (pt) | 2019-09-24 |
Family
ID=41110533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0912043A BRPI0912043A2 (pt) | 2008-05-30 | 2009-05-28 | métodos de tratamento de doença associada à cinesina meiótica |
Country Status (12)
Country | Link |
---|---|
US (3) | US8629118B2 (pt) |
EP (1) | EP2315594B1 (pt) |
JP (3) | JP5735417B2 (pt) |
KR (1) | KR20110022000A (pt) |
CN (1) | CN102316877A (pt) |
AU (1) | AU2009260527A1 (pt) |
BR (1) | BRPI0912043A2 (pt) |
CA (1) | CA2725911A1 (pt) |
EA (1) | EA201071422A1 (pt) |
ES (1) | ES2633930T3 (pt) |
MX (1) | MX2010012931A (pt) |
WO (1) | WO2009155025A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486449B2 (en) | 2007-10-09 | 2016-11-08 | Malka COHEN-ARMON | Cancer therapy |
JP5735417B2 (ja) | 2008-05-30 | 2015-06-17 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 減数分裂期キネシンに関連する疾患を治療する方法 |
EP2827869A4 (en) | 2012-03-23 | 2015-09-23 | Dennis Brown | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO |
US20150309031A2 (en) * | 2013-12-05 | 2015-10-29 | Novazoi Theranostics | Compositions and methods for prognosis and treatment of cancer |
WO2015130953A1 (en) * | 2014-02-28 | 2015-09-03 | Novazoi Theranostics, Inc. | Method for determining the risk profile of neoplastic tissue |
CN113456633A (zh) * | 2021-06-11 | 2021-10-01 | 广西医科大学 | 红海海绵素a在制备抗肺癌侵袭转移药物中的应用 |
WO2023131690A1 (en) | 2022-01-10 | 2023-07-13 | Merck Patent Gmbh | Substituted heterocycles as hset inhibitors |
WO2024099898A1 (en) | 2022-11-07 | 2024-05-16 | Merck Patent Gmbh | Substituted bi-and tricyclic hset inhibitors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) * | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6410254B1 (en) * | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
WO2000063353A1 (en) * | 1999-04-20 | 2000-10-26 | Cytokinetics | Human kinesins and methods of producing and purifying human kinesins |
US7416856B2 (en) * | 1999-05-18 | 2008-08-26 | Cytokinetics, Inc. | High sensitivity assay for detection of nucleoside diphosphate production |
US6743599B1 (en) * | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US7202051B1 (en) * | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
IL158083A0 (en) * | 2001-03-29 | 2004-03-28 | Bristol Myers Squibb Co | A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR |
US20040009156A1 (en) | 2001-10-12 | 2004-01-15 | Christoph Reinhard | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
US7163927B2 (en) * | 2002-05-23 | 2007-01-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20050100508A1 (en) * | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
US20070026424A1 (en) * | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
AR062200A1 (es) * | 2006-08-04 | 2008-10-22 | Aeterna Zentaris Gmbh | Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas |
US20080051463A1 (en) * | 2006-08-04 | 2008-02-28 | Aeterna Zentaris Gmbh | Anthracene compounds and their use for treating benign and malignant tumor disorders |
WO2008132752A2 (en) * | 2007-05-01 | 2008-11-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for predicting cancer metastasis |
JP5735417B2 (ja) | 2008-05-30 | 2015-06-17 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 減数分裂期キネシンに関連する疾患を治療する方法 |
-
2009
- 2009-05-28 JP JP2011511802A patent/JP5735417B2/ja not_active Expired - Fee Related
- 2009-05-28 WO PCT/US2009/045406 patent/WO2009155025A1/en active Application Filing
- 2009-05-28 ES ES09767337.0T patent/ES2633930T3/es active Active
- 2009-05-28 CN CN2009801299003A patent/CN102316877A/zh active Pending
- 2009-05-28 KR KR20107029850A patent/KR20110022000A/ko not_active Application Discontinuation
- 2009-05-28 BR BRPI0912043A patent/BRPI0912043A2/pt not_active IP Right Cessation
- 2009-05-28 EP EP09767337.0A patent/EP2315594B1/en active Active
- 2009-05-28 US US12/994,920 patent/US8629118B2/en active Active
- 2009-05-28 AU AU2009260527A patent/AU2009260527A1/en not_active Abandoned
- 2009-05-28 MX MX2010012931A patent/MX2010012931A/es not_active Application Discontinuation
- 2009-05-28 EA EA201071422A patent/EA201071422A1/ru unknown
- 2009-05-28 CA CA 2725911 patent/CA2725911A1/en not_active Abandoned
-
2013
- 2013-12-11 US US14/103,520 patent/US8962592B2/en not_active Expired - Fee Related
-
2015
- 2015-01-07 US US14/591,678 patent/US9645136B2/en not_active Expired - Fee Related
- 2015-02-04 JP JP2015020184A patent/JP6132409B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-31 JP JP2016108400A patent/JP6184556B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110190374A1 (en) | 2011-08-04 |
ES2633930T3 (es) | 2017-09-26 |
JP2015131813A (ja) | 2015-07-23 |
US9645136B2 (en) | 2017-05-09 |
EA201071422A1 (ru) | 2011-08-30 |
JP2011525174A (ja) | 2011-09-15 |
JP5735417B2 (ja) | 2015-06-17 |
EP2315594A1 (en) | 2011-05-04 |
CA2725911A1 (en) | 2009-12-23 |
JP2016169224A (ja) | 2016-09-23 |
US20150111786A1 (en) | 2015-04-23 |
CN102316877A (zh) | 2012-01-11 |
JP6184556B2 (ja) | 2017-08-23 |
AU2009260527A1 (en) | 2009-12-23 |
US8962592B2 (en) | 2015-02-24 |
JP6132409B2 (ja) | 2017-05-24 |
KR20110022000A (ko) | 2011-03-04 |
EP2315594B1 (en) | 2017-05-17 |
MX2010012931A (es) | 2011-02-24 |
US20140106344A1 (en) | 2014-04-17 |
US8629118B2 (en) | 2014-01-14 |
WO2009155025A1 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
BRPI0910854A2 (pt) | métodos de tratamento | |
LTPA2016041I1 (lt) | Gydymo būdai panaudojant vaistus - amoniako gaudykles | |
BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
BRPI0917567A2 (pt) | tratamento de doença respiratória | |
BRPI0810206A2 (pt) | Método de tratar câncer | |
BRPI0908276A2 (pt) | Métodos de tratar dor inflamatória | |
BRPI0814624A2 (pt) | Tratamento de doença neurodegenerativa progresiva com ibudilaste | |
BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
BRPI0919426A2 (pt) | métodos melhorado de exposição de rna | |
BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
BRPI0914841A2 (pt) | aparelho de massagem | |
SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
BRPI0815551A2 (pt) | Tratamento através de hucbc de doença beta-amiloide | |
DE602008004368D1 (de) | Endoskop-Behandlungswerkzeug | |
BRPI0912043A2 (pt) | métodos de tratamento de doença associada à cinesina meiótica | |
BRPI0919127A2 (pt) | métodos para tratamento de água | |
DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
BRPI0814876A2 (pt) | Análogos de pirona fosforilados e métodos | |
DK2173831T3 (da) | Brøndbehandling | |
BRPI0810559A2 (pt) | Macadores de doenças | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
DE502008000740D1 (de) | Rollosystem | |
FI20085693A0 (fi) | Biosignaalin prosessointi | |
BRPI1010516A2 (pt) | Métodos de tratamento de edema relacionados à isquemia-reperfusão |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |